Literature DB >> 2994222

Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus.

J A Hoxie, B S Haggarty, J L Rackowski, N Pillsbury, J A Levy.   

Abstract

Infection of normal peripheral blood T cells by the acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) was evaluated in long-term cultures of helper-inducer T cells (T4 cells). Cells that were inoculated with ARV and maintained in medium supplemented with interleukin-2 remained productively infected with this virus for more than 4 months in culture, although they showed no cytopathic effects characteristic of acute ARV infection. The presence of replicating virus was demonstrated by reverse transcriptase activity of culture fluids and by viral antigens and budding particles detected on cells by immunofluorescence and electron microscopy. Virus produced in these cultures remained infectious and could induce cytopathic effects and viral antigens in uninfected lymphoid cells. The finding that normal lymphocytes may be productively infected by an AIDS retrovirus in the absence of cell death suggests that a range of biologic effects may occur after infection in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994222     DOI: 10.1126/science.2994222

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  48 in total

1.  Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.

Authors:  A Karpas; M Lowdell; S K Jacobson; F Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

2.  Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo.

Authors:  J A Mikovits; N C Lohrey; R Schulof; J Courtless; F W Ruscetti
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

3.  The effect of bioreactor configuration on production of HIV and cell-virus interaction.

Authors:  J B Clarke; J B Griffiths
Journal:  Cytotechnology       Date:  1990-09       Impact factor: 2.058

4.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication.

Authors:  P A Luciw; C Cheng-Mayer; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

6.  Most CD4+ T cells from human immunodeficiency virus-1 infected patients can undergo prolonged clonal expansion.

Authors:  E Langhoff; J McElrath; H J Bos; J Pruett; A Granelli-Piperno; Z A Cohn; R M Steinman
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

7.  Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study.

Authors:  J M Orenstein; M S Meltzer; T Phipps; H E Gendelman
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  Transcellular activation of the human immunodeficiency virus type 1 long terminal repeat in T lymphocytes requires CD4-gp120 binding.

Authors:  A Marcuzzi; I Lowy; O K Weinberger
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

10.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.